ArticleJournal of managed care & specialty pharmacy2021

Cost-effectiveness of obinutuzumab versus rituximab biosimilars for previously untreated follicular lymphoma.

Scott J Spencer et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.